Études cliniques

A Moleac, comprendre les propriétés de nos innovations est une de nos priorités. Nous continuons d’investir dans la recherche et le développement pour utiliser au mieux le potentiel de notre produit en neurologie. Moleac a travaillé avec des experts de renommée mondiale, dans plus de 20 centres de recherche. Vous trouverez ci-dessous une liste des essais cliniques auxquels nous avons participé :

Pour plus d’informations à propos des essais cliniques dans lesquels nous sommes engagés, veuillez contacter notre équipe médicale à l’adress medical@moleac.com

Accident ischémique
NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.

Publication : Gan R, et al. Cerebrovasc Dis 2008. DOI: 10.1159/000126919

Taille de l’échantillon : 64

NeuroAiD in Stroke Recovery.

Publication : Siow C, Eur Neurol 2008. DOI: 10.1159/000155220

Taille de l’échantillon : 10

Accident ischémique
A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).

Publication : Kong KH, et al. Cerebrovasc Dis 2009.DOI: 10.1159/000247001

Taille de l’échantillon : 40

Sponsor : Moleac Pte Ltd.

NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.

Publication : Chen C, et al. Stroke 2009. DOI: 10.1161/STROKEAHA.108.531616

Taille de l’échantillon : 605

Sponsor : Tianjin University of Traditional Chinese Medicine

Traumatisme crânien
Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.

Publication : Yeo TT, et al. Poster WSC Seoul 2010.

Taille de l’échantillon : 3

Accident ischémique
The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory.
NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia.

Publication : Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003

Taille de l’échantillon : 40

Sponsor : Moleac Pte. Ltd.

Accident ischémique
The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.

Publication : Navarro JC, et al. Rehabil Res Pract 2012. DOI: 10.1155/2012/506387

Taille de l’échantillon : 30

Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.

Publication : Harandi AA, et al. Stroke Res Treat 2011. DOI: 10.4061/2011/721613

Taille de l’échantillon : 150

Sponsor : Shahid Beheshti University

Accident ischémique
Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.

Publication : Chen C, et al. Stroke 2013. DOI: 10.1161/STROKEAHA.113.002055

Taille de l’échantillon : 1099

Sponsor : CHIMES Society

Troubles cognitifs et démence
Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.

Publication : Harandi AA, et al. Brit Med Med Res 2013.

Taille de l’échantillon : 124

Sponsor : Shahid Beheshti University of Medical Sciences

Accident ischémique
A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.
Accident ischémique
CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.

Publication : Venketasubramanian N, et al. Cerebrovascular Diseases 2015. DOI: 10.1159/000382082

Taille de l’échantillon : 880

Sponsor : CHIMES Society

Troubles cognitifs et démence
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer’s Disease: A Multicenter, Randomized Controlled Trial.
Accident ischémique
NurAiD-II in stroke recovery: scientific reasoning and real-world evidence.

Publication : De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017.

Troubles cognitifs et démence
MLC601 in vascular dementia: an efficacy and safety pilot study.
Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study.
Traumatisme crânien
MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial.

Publication : A. Theadom et al. Eur J Neurol. 2018 Apr 3. DOI: 10.1111/ene.13653

Taille de l’échantillon : 78

Others
Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury.

Publication : Kumar JC et al. JMIR Res Protoc 2016. DOI: 10.2196/resprot.6275

Taille de l’échantillon : 26

Sponsor : Moleac Pte. Ltd.

The NeuroAiD Safe Treatment (NeST) Registry: a protocol.

Publication : Venketasubramanian N, et al. BJM Open 2015. DOI:10.1136/bmjopen-2015-009866

Taille de l’échantillon : 460

Sponsor : CHIMES Society

The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES).

Publication : Chen C, et al. Cerebrovasc Dis 2013.DOI: 10.1159/000346234

Taille de l’échantillon : 103

Sponsor : National University Hospital, Singapore

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.